Article
Assessing emergence risk of double-resistant and triple-resistant genotypes of Plasmodium falciparum.
Nature communications - 15 Feb 2024
Li Eric Zhewen, Nguyen Tran Dang, Tran Thu Nguyen-Anh, Zupko Robert J, Boni Maciej F
Abstract excerpt
Delaying and slowing antimalarial drug resistance evolution is a priority for malaria-endemic countries. Until novel therapies become available, the mainstay of antimalarial treatment will continue to be artemisinin-based combination therapy (ACT). Deployment of different ACTs can be optimized to minimize evolutionary pressure for drug resistance by deploying them as a set of co-equal multiple first-line...
Topics
- Humans
- Antimalarials
- Drug Resistance
- Folic Acid Antagonists
- Genotype
- Malaria
- Malaria, Falciparum
- Plasmodium falciparum
